Literature DB >> 11413125

Clinical guidelines on the management of hepatitis C.

J C Booth1, J O'Grady, J Neuberger.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11413125      PMCID： PMC1766890          DOI： 10.1136/gut.49.suppl_1.i1

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  159 in total

1.  A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C.

Authors:  M Rumi; E Del Ninno; M L Parravicini; R Romeo; R Soffredini; M F Donato; J Wilber; A Russo; M Colombo
Journal:  Hepatology       Date:  1996-12       Impact factor: 17.425

2.  Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study.

Authors:  G Dusheiko; J Main; H Thomas; O Reichard; C Lee; A Dhillon; S Rassam; A Fryden; H Reesink; M Bassendine; G Norkrans; T Cuypers; N Lelie; P Telfer; J Watson; C Weegink; P Sillikens; O Weiland
Journal:  J Hepatol       Date:  1996-11       Impact factor: 25.083

3.  HCV confirmatory testing of blood donors.

Authors:  E A Follett; B C Dow; F McOmish; P L Yap; W Hughes; R Mitchell; P Simmonds
Journal:  Lancet       Date:  1991-10-19       Impact factor: 79.321

4.  Severity of liver disease with different hepatitis C viral clones.

Authors:  G Pozzato; M Moretti; F Franzin; L S Crocè; C Tiribelli; T Masayu; S Kaneko; M Unoura; K Kobayashi
Journal:  Lancet       Date:  1991-08-24       Impact factor: 79.321

5.  Hepatitis C virus infection in Egyptian volunteer blood donors in Riyadh.

Authors:  A A Saeed; A M al-Admawi; A al-Rasheed; D Fairclough; R Bacchus; C Ring; J Garson
Journal:  Lancet       Date:  1991-08-17       Impact factor: 79.321

6.  Transmission of hepatitis C virus by organ transplantation.

Authors:  B J Pereira; E L Milford; R L Kirkman; A S Levey
Journal:  N Engl J Med       Date:  1991-08-15       Impact factor: 91.245

7.  High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus.

Authors:  J I Esteban; J C López-Talavera; J Genescà; P Madoz; L Viladomiu; E Muñiz; C Martin-Vega; M Rosell; H Allende; X Vidal
Journal:  Ann Intern Med       Date:  1991-09-15       Impact factor: 25.391

8.  Hepatitis C in hospital employees with needlestick injuries.

Authors:  K Kiyosawa; T Sodeyama; E Tanaka; Y Nakano; S Furuta; K Nishioka; R H Purcell; H J Alter
Journal:  Ann Intern Med       Date:  1991-09-01       Impact factor: 25.391

9.  Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.

Authors:  G Mazzella; E Accogli; S Sottili; D Festi; M Orsini; A Salzetta; V Novelli; A Cipolla; C Fabbri; A Pezzoli; E Roda
Journal:  J Hepatol       Date:  1996-02       Impact factor: 25.083

10.  Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis.

Authors:  X Causse; H Godinot; M Chevallier; P Chossegros; F Zoulim; D Ouzan; J P Heyraud; T Fontanges; J Albrecht; C Meschievitz
Journal:  Gastroenterology       Date:  1991-08       Impact factor: 22.682
View more
  35 in total

1.  HCV infection should be managed in specialist centres.

Authors:  J L Brown
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

2.  Sentinel laboratory surveillance of hepatitis C antibody testing in England: understanding the epidemiology of HCV infection.

Authors:  L J Brant; M Hurrelle; M A Balogun; P Klapper; F Ahmad; E Boxall; A Hale; V Hollyoak; I B Ibrahim; W Irving; R Meigh; K J Mutton; B C Patel; W K Paver; S Pugh; C Taylor; A J Turner; M E Ramsay
Journal:  Epidemiol Infect       Date:  2006-07-13       Impact factor: 2.451

Review 3.  Ophthalmologic complications of antiviral therapy in hepatitis C treatment.

Authors:  Roderick O'Day; Mark C Gillies; Golo Ahlenstiel
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

4.  Statistical linkage analysis of substitutions in patient-derived sequences of genotype 1a hepatitis C virus nonstructural protein 3 exposes targets for immunogen design.

Authors:  Ahmed A Quadeer; Raymond H Y Louie; Karthik Shekhar; Arup K Chakraborty; I-Ming Hsing; Matthew R McKay
Journal:  J Virol       Date:  2014-04-23       Impact factor: 5.103

Review 5.  Liver transplantation for hepatitis C virus related liver disease.

Authors:  I Gee; G Alexander
Journal:  Postgrad Med J       Date:  2005-12       Impact factor: 2.401

6.  The swinging thyroid in hepatitis C infection and interferon therapy.

Authors:  Huy A Tran
Journal:  BMJ Case Rep       Date:  2009-09-15

7.  Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy.

Authors:  C Skipper; J M Guy; J Parkes; P Roderick; W M Rosenberg
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

8.  Impact of Hepatitis C Virus/Schistosoma mansoni Coinfection on the Circulating Levels of HCV-NS4 Protein and Extracellular-Matrix Deposition in Patients with Different Hepatic Fibrosis Stages.

Authors:  Abdelfattah M Attallah; Sanaa O Abdallah; Mohamed S Albannan; Mohamed M Omran; Ahmed A Attallah; Khaled Farid
Journal:  Am J Trop Med Hyg       Date:  2016-08-15       Impact factor: 2.345

Review 9.  Management strategies for hepatitis C virus infection in children.

Authors:  Suzanne M Davison; Deirdre A Kelly
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

10.  Prevalence of HBV and HCV among blood donors in Kosovo.

Authors:  Hajrullah Fejza; Skender Telaku
Journal:  Virol J       Date:  2009-02-13       Impact factor: 4.099
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.